Cargando...
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type...
Guardado en:
| Publicado en: | Pharmaceuticals (Basel) |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8308490/ https://ncbi.nlm.nih.gov/pubmed/34209967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14070632 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|